Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beam Therapeutics Inc.BEAM · Entity 4227 | Director · CEO | June 29, 2026 | July 01, 2026 |
| Verve Therapeutics, Inc.VERV · Entity 11259 | Director | June 09, 2022 | June 13, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beam Therapeutics Inc.
Report date June 29, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,047,205 |
Ending reported balance
After 2026-06-30 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-06-29 · Exercise / conversion · Acquired 18,663 · Balance 1,065,868 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Row 2 · 2026-06-29 · Exercise / conversion · Acquired 6,337 · Balance 1,072,205 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Row 3 · 2026-06-29 · Sale · Disposed 13,421 · Balance 1,058,784 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.55 to $35.50, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 4 · 2026-06-29 · Sale · Disposed 11,579 · Balance 1,047,205 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.60 to $36.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 5 · 2026-06-30 · Exercise / conversion · Acquired 25,000 · Balance 1,072,205 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Row 6 · 2026-06-30 · Sale · Disposed 23,100 · Balance 1,049,105 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.80 to $34.71, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 7 · 2026-06-30 · Sale · Disposed 1,900 · Balance 1,047,205 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.83 to $34.85, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.67 · Expires 2028-05-08 | Direct | 9 |
Reported balance
After 2026-06-29 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-06-29 · Exercise / conversion · Disposed 18,663 · Balance 9 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F6: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2028-07-13 | Direct | 230,804 |
Reported balance
After 2026-06-29 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-06-29 · Exercise / conversion · Disposed 6,337 · Balance 230,804 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F7: On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2028-07-13 | Direct | 205,804 |
Reported balance
After 2026-06-30 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-06-30 · Exercise / conversion · Disposed 25,000 · Balance 205,804 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F7: On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter. |
| Common StockSEC Table I · non-derivative | IndirectBy John M. Evans, III 2018 Irrevocable Trust | 103,000 |
Reported balance
Holding disclosure · report date 2026-06-29 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 103,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.55 to $35.50, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.60 to $36.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.80 to $34.71, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.83 to $34.85, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.
F7: On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter.
Verve Therapeutics, Inc.
Report date June 09, 2022 · Filed June 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.04 · Expires 2032-06-08 | Direct | 15,500 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 15,500 · Balance 15,500 F1: This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the "Vesting Commencement Date") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the "Vesting Commencement Date") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2022 Filed Feb 2, 2022 23:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 100,000 | $1.03 | $103,000.00 |
DisclosureSEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 9 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 23:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 3,978 | $68.15 | $271,100.70 |
DisclosureSEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 8 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 938,825 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $68.00 to $68.60, inclusive. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 23:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 13,535 | $67.44 | $912,800.40 |
DisclosureSEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 7 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 942,803 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.00 to $67.99, inclusive. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 23:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 6,337 | $66.55 | $421,727.35 |
DisclosureSEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 6 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 956,338 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.09 to $66.94, inclusive. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 23:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 3,177 | $65.49 | $208,061.73 |
DisclosureSEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 5 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 962,675 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.20 to $65.99, inclusive. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 23:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 2,172 | $64.47 | $140,028.84 |
DisclosureSEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 4 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 965,852 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.21 to $64.50, inclusive. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 23:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 801 | $63.79 | $51,095.79 |
DisclosureSEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 968,024 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $63.60 to $63.96, inclusive. Read SEC document |
| November 16, 2021 Filed Feb 2, 2022 23:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | GiftCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 968,825 Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:21 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,700 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000899243-21-039697 · doc4.xml · derivative · entry 10 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,645 Underlying: Common Stock · 27,700 shares Expires 2028-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:21 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 400 | $85.24 | $34,096.00 |
DisclosureSEC source: 0000899243-21-039697 · doc4.xml · nonDerivative · entry 9 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 183,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $85.07 to $85.31, inclusive. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:21 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 7,566 | $84.45 | $638,948.70 |
DisclosureSEC source: 0000899243-21-039697 · doc4.xml · nonDerivative · entry 8 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 183,400 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $84.07 to $84.98, inclusive. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:21 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 9,863 | $83.49 | $823,461.87 |
DisclosureSEC source: 0000899243-21-039697 · doc4.xml · nonDerivative · entry 7 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 190,966 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $83.08 to $83.98, inclusive. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:21 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 2,171 | $82.71 | $179,563.41 |
DisclosureSEC source: 0000899243-21-039697 · doc4.xml · nonDerivative · entry 6 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 200,829 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $82.465 to $82.97, inclusive. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:21 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 701 | $85.19 | $59,718.19 |
DisclosureSEC source: 0000899243-21-039697 · doc4.xml · nonDerivative · entry 5 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,033,525 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $85.03 to $85.32, inclusive. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:21 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 10,444 | $84.45 | $881,995.80 |
DisclosureSEC source: 0000899243-21-039697 · doc4.xml · nonDerivative · entry 4 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,034,226 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $84.005 to $84.98, inclusive. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:21 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 13,406 | $83.47 | $1,118,998.82 |
DisclosureSEC source: 0000899243-21-039697 · doc4.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,044,670 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $83.04 to $83.98, inclusive. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:21 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 3,149 | $82.72 | $260,485.28 |
DisclosureSEC source: 0000899243-21-039697 · doc4.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,076 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $82.465 to $82.995, inclusive. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:21 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 27,700 | $1.03 | $28,531.00 |
DisclosureSEC source: 0000899243-21-039697 · doc4.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,061,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 22:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000899243-21-033848 · doc4.xml · derivative · entry 8 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,345 Underlying: Common Stock · 12,000 shares Expires 2028-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 22:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 12,000 | $1.03 | $12,360.00 |
DisclosureSEC source: 0000899243-21-033848 · doc4.xml · nonDerivative · entry 7 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,033,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 22:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 300 | $101.00 | $30,300.00 |
DisclosureSEC source: 0000899243-21-033848 · doc4.xml · nonDerivative · entry 6 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 203,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 22:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 5,456 | $100.35 | $547,509.60 |
DisclosureSEC source: 0000899243-21-033848 · doc4.xml · nonDerivative · entry 5 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 203,300 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $100.04 to $100.99, inclusive. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 22:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 9,704 | $99.53 | $965,839.12 |
DisclosureSEC source: 0000899243-21-033848 · doc4.xml · nonDerivative · entry 4 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 208,756 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $99.01 to $99.95, inclusive. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 22:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 3,140 | $98.74 | $310,043.60 |
DisclosureSEC source: 0000899243-21-033848 · doc4.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 218,460 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $98.33 to $98.99, inclusive. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 22:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,000 | $97.50 | $97,500.00 |
DisclosureSEC source: 0000899243-21-033848 · doc4.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 221,600 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $97.22 to $97.85, inclusive. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 22:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 400 | $96.38 | $38,552.00 |
DisclosureSEC source: 0000899243-21-033848 · doc4.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 222,600 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $96.07 to $96.97, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy · Derivative | 25,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · derivative · entry 16 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,345 Underlying: Common Stock · 25,000 shares Expires 2028-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 2,250 | $112.62 | $253,395.00 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 14 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,021,525 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $112.00 to $112.99, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 3,456 | $111.51 | $385,378.56 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 13 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,023,775 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $111.04 to $111.99, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 3,982 | $110.54 | $440,170.28 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 12 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,027,231 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $110.04 to $110.99, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 4,800 | $109.58 | $525,984.00 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 11 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,031,213 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $109.01 to $109.98, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 800 | $108.65 | $86,920.00 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 10 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036,013 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $108.32 to $108.99, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 167 | $107.31 | $17,920.77 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 9 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036,813 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $107.29 to $107.33, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 500 | $106.48 | $53,240.00 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 8 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036,980 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $106.12 to $106.77, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,800 | $105.44 | $189,792.00 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 7 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,037,480 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $105.02 to $105.98, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,336 | $104.40 | $139,478.40 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 6 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,039,280 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $104.00 to $104.96, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 2,864 | $103.52 | $296,481.28 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 5 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,040,616 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $103.21 to $103.96, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 100 | $102.00 | $10,200.00 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 4 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,043,480 Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 2,300 | $101.27 | $232,921.00 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,043,580 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $101.00 to $101.85, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 645 | $100.69 | $64,945.05 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,045,880 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $100.25 to $100.99, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 25,000 | $1.03 | $25,750.00 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,046,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | OtherCommon Stock | 32 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026781 · doc4.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,021,525 F1 · kind: Distribution of BEAM common stock held by ARCH Venture Fund IX, L.P. to its partners for no consideration. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | OtherCommon Stock | 32 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026781 · doc4.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,021,493 F1 · kind: Distribution of BEAM common stock held by ARCH Venture Fund IX, L.P. to its partners for no consideration. Read SEC document |
| June 25, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | OtherCommon Stock | 32 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026781 · doc4.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,021,461 F1 · kind: Distribution of BEAM common stock held by ARCH Venture Fund IX, L.P. to its partners for no consideration. Read SEC document |
| April 23, 2021 Filed Apr 23, 2021 20:45 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000899243-21-016869 · doc4.xml · derivative · entry 8 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,345 Underlying: Common Stock · 6,000 shares Expires 2028-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
| April 23, 2021 Filed Apr 23, 2021 20:45 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 6,000 | $1.03 | $6,180.00 |
DisclosureSEC source: 0000899243-21-016869 · doc4.xml · nonDerivative · entry 6 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,021,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 20:45 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 2,994 | $71.79 | $214,939.26 |
DisclosureSEC source: 0000899243-21-016869 · doc4.xml · nonDerivative · entry 5 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,015,429 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: These shares were sold in multiple transactions ranging from $71.68 to $71.92 inclusive. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 20:45 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 9,869 | $71.38 | $704,449.22 |
DisclosureSEC source: 0000899243-21-016869 · doc4.xml · nonDerivative · entry 4 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,018,423 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: These shares were sold in multiple transactions ranging from $70.68 to $71.66 inclusive. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 20:45 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 5,595 | $70.23 | $392,936.85 |
DisclosureSEC source: 0000899243-21-016869 · doc4.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,028,292 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: These shares were sold in multiple transactions ranging from $69.68 to $70.68 inclusive. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 20:45 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 5,079 | $69.02 | $350,552.58 |
DisclosureSEC source: 0000899243-21-016869 · doc4.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,033,887 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: These shares were sold in multiple transactions ranging from $68.67 to $69.55 inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.